Between September 1986 and June 1997, 24 children with high-risk ALL in CR1 were allografted after TAM (fractionated TBI, high-dose Ara-C, and melphalan; n ¼ 10) or BAM protocol (busulfan, high-dose Ara-C, and melphalan; n ¼ 14). The EFS for transplants from sibling donors was 33% with TAM and 62% with BAM (P ¼ 0.148). The probability of acute GvHD was 70% with TAM and 15% with BAM (P ¼ 0.003). Four of 17 evaluable patients relapsed: one after TAM and three after BAM. In all, 46 other children transplanted in CR beyond CR1 were studied for sequelae. Long-term side effects were more frequent in TAM vs BAM. In children with ALL, busulfan may be a good alternative to TBI to improve the quality of life.
late effect; children HSCT is generally used for children with very high risk ALL in CR1, or ALL in CR2 or beyond. [1] [2] [3] Total body irradiation (TBI), used in the conditioning regimen to increase the antileukemic effect of the transplant, 4-7 is associated with long-term complications. [8] [9] [10] Busulfan (Bu) is used as an alternative to TBI; particularly in young children. 11, 12 From 1985, we have used one of two intensified conditioning regimens: TAM (fractionated TBI, high-dose Ara-C, melphalan), 7 and BAM (Bu, high-dose Ara-C, melphalan) which was recommended by the CLCG-EORTC group. We report our experience with these two regimens in 24 ALL patients transplanted in CR1 between September 1986 and June 1997. Long-term outcomes were studied in these patients as well as 46 other ALL patients transplanted in advanced CR with the same regimens in the same institution over the same period of time.
Patients and methods

Characteristics of patients evaluated for antileukemic effect (CR1)
A total of 24 children with ALL in CR1 received HSCT using the TAM (n ¼ 10) or the BAM (n ¼ 14) preparative protocols. HSCT consisted of bone marrow except in the two patients transplanted with umbilical cord blood in the TAM group. Patients who received T-cell-depleted marrow were excluded from this study. Patients were initially treated with protocols EORTC 58832 (n ¼ 3) or 58881 (n ¼ 21). 13 Patient characteristics and eligibility criteria for transplantation in CR1 are listed in Table 1 .
Characteristics of patients evaluated for long-term sequelae (CR1, CR2, CR3, CR4) ALL patients in subsequent CR were transplanted following conditioning using the TAM protocol in 42 cases (36 CR2, five CR3, one CR4) or with the BAM protocol in four cases (two CR2, two CR3). Among the 36 CR2 patients, 11 patients had very early relapse (VER), p18 months after diagnosis; 16 patients had early relapse (ER), between 19 months after diagnosis and up to 6 months after the end of therapy; nine patients had late relapse (LR). In this CR2 group, 19 patients had isolated bone marrow relapses, 12 had bone marrow relapses combined with extramedullary sites (seven CNS, one thymus, two testicular and two CNS plus testicular) and five patients had extramedullary sites of relapse: three CNS (two VER, one ER), one testicular and one epidural tumor. Among the five patients in CR3, three patients had bone marrow relapses, two patients had an isolated extramedullary site of relapse (one testicular and one ocular). One patient in CR4 had successively testicular, marrow, and CNS relapses. In the BAM group, two patients had VER marrow relapse and two had marrow relapse in CR3, having received cranial and vertebral irradiation before. Patients with initial testicular involvement or with prior testicular relapse were given a median dose of 24 Gy (range: 16-25 Gy) to the testicles. Patients in testicular CR1 relapse at the time of transplant were given a prophylactic booster dose of 4 Gy in two fractions to the testicles, during fTBI until the end of 1992. Prophylactic cranial irradiation was given to only four patients in the TAM group until 1986 at a median dose of 24 Gy (range: 18-25 Gy). None of the CR1 patients of the BAM group received irradiation.
All surviving patients were included in a prospective study for evaluation and collection of late effects.
For that purpose, the follow-up visits were initially planned monthly for 6 months, then every 3 months until the end of the second year post-BMT, and then every 6 months until 10 years post transplant, and yearly afterwards. Data collected included: bi-annual check-up for growth with construction of curves for height, weight, bone age, and growth velocity for comparison with standard growth curves in normal children (age and sex matched). Growth impairment below 4 cm per year or poor height velocity required growth-hormone (GH) evaluation after pharmacological stimulation. If the peak GH was below 10 ng/ml, a second determination with a different stimulus was performed. The check-up for thyroid function consisted of palpation of the thyroid, annual thyroid ultrasound, and measurement of basal thyroid hormones (thyroxin, TSH). TSH levels above 5 UI/ml or enhanced response to TRH was considered to represent compensated hypothyroidism. Hypothyroidism was diagnosed when TSH and thyroxin levels were low. The check-up for puberty consisted of determining the stage of puberty according to Tanner development scores. Ovarian function was studied by using basal LH, FSH, and estradiol levels, as well as ultrasound assessment of ovaries and uterus. Testicular function was assessed by testicular volume using the Prader orchidometer, and basal LH, FSH, and testosterone. Other evaluations consisted of pulmonary function, dental, and ophthalmologic examination.
Conditioning regimen. In the TAM group, all patients received fTBI in six fractions over 3 days for a total dose of 12 Gy, followed by Ara-C 3 g/m 2 every 12 h intravenously over 1 h for eight doses (n ¼ 35) or six doses (n ¼ 12) or four doses (n ¼ 5) and by a single dose of melphalan (140 mg/m 2 ) infused over 1 h. All children had lung shielding resulting in a median lung dose of 10 Gy. In the BAM group, patients received busulfan 480 mg/m 2 total dose given orally every 6 h over 4 days, followed by Ara-C 3 g/m 2 for eight doses (n ¼ 7) or six doses (n ¼ 9) or four doses (n ¼ 2) and by a single dose of melphalan 140 mg/m 2 .
Histocompatibility. HLA data for CR1 patients and patients in subsequent CR are summarized in Table 2 .
Engraftment and evaluation of regimen-related toxicity. Engraftment was defined as occurring on the first of three consecutive days with neutrophils X0.5 Â 10 9 /l. Granulocyte colony-stimulating factor (GCSF) was given for all unrelated transplants (n ¼ 12) or mismatched transplants (n ¼ 5) or in the presence of severe mucositis, infection or delayed engraftment (n ¼ 4). Regimen-related toxicity was evaluated and scored according to the WHO criteria.
GvHD prophylaxis, assessment, and treatment. GvHD prophylaxis consisted of short-course methotrexate (MTX) plus cyclosporine (CsA) except in the five earliest transplanted patients with TAM protocol and in syngeneic transplant. Patients transplanted with an unrelated donor received additional prophylaxis with rabbit antithymocyte globulin (Thymoglobuline s ), at a cumulative dose of 20 mg/kg prior to transplant in four infusions on days À7, À5, À3, and À1. Acute GvHD was graded according to the Glucksberg criteria. Primary treatment of acute GvHD consisted of glucocorticoids.
Informed consent. The risks of the BMT procedure and its expected benefits and limits were fully explained to the family. Parents of all patients provided informed consent before transplantation.
Statistics. All patients who received second transplants have been excluded from the analysis of sequelae.
The cumulative events were summarized as Kaplan-Meier curves using SPSS software (version 10.0, SPSS Inc., Chicago, IL, USA). An event was defined as a relapse or death (whatever the cause of death). The date of the first event was used in calculating the event-free survival (EFS), whose duration was calculated from the date of BMT until the date of death or last known date to be alive. The EFS was compared in the two groups in CR1 by using the log-rank test. The difference was stated as significant when the P value was less than 0.05. Kaplan-Meier curves in patients transplanted from an HLA-identical sibling in CR1 were calculated. Statistical analysis was performed at the end of 2001.
Results
Antileukemic effect of TAM vs BAM regimens (CR1)
Regimen-related toxicity. Regimen-related nephrotoxicity was observed in two patients in the TAM group and two patients in the BAM group. One patient in the TAM group and two patients in the BAM group developed metabolic dysfunction. Reversible VOD was seen in three patients in the BAM group. Another patient of this last group suffered from transient neurototoxicity.
Engraftment. Eight out of 10 patients in the TAM group (two early deaths) were evaluable for engraftment. The median time to engraftment was 24 days (20-30) with G-CSF (n ¼ 7). For the two patients who did not receive G-CSF the times to engraftment were 24 and 50 days. All patients in the BAM group showed evidence of engraftment. The median time to engraftment was 20 days (14-27) with G-CSF (n ¼ 4) and 26 days (20-35) without.
Survival. The 7 years EFS in CR1 was 57% for BAM and 50% for TAM (log rank; P ¼ 0.65) (Figure 1 ). EFS in CR1 for sibling donors was 33% for the TAM group and 62% for the BAM group, but the difference was not statistically significant (log rank; P ¼ 0.148). However, the difference in overall survival (OS) in these two groups was significant (TAM: 33%, BAM: 77% (P ¼ 0.045). The Kaplan-Meier estimate of the probability for survival at 7 years was 66% for all patients in RC1.
Transplant-related mortality (TRM). In the BAM group, three patients died (invasive aspergillosis, metabolic disorders, thrombotic microangiopathy). In the TAM group, four patients died (GvHD and bone marrow failure, capillary leak syndrome, sudden death, CNS hematoma). The TRM in CR1 was not different in the two groups (P ¼ 0.296).
GvHD. Acute GvHD occurred in seven patients in the TAM group at a median time of 18 days (5-30); three patients had grade II: two patients grade III in one genoidentical and one phenoidentical unrelated transplant. In the BAM group, only four patients had grade I-II acute GvHD. The probability of acute GvHD in TAM and BAM groups for patients transplanted in CR1 were respectively, 70 and 15% (log rank P ¼ 0.003).
Chronic GvHD occurred in three patients among six patients evaluable in the TAM group. Chronic GvHD was extensive in the three cases (one unrelated transplant and two genoidentical transplants). In the BAM group, among the 11 evaluable patients, only one patient suffered from chronic GvHD with clinical chronic bronchiolitis.
Leukemia relapse. Four out of 24 patients relapsed (17%), one out of 10 patients in the TAM group (10%) and three out of 14 patients in the BAM group (21%). The only site of relapse was bone marrow. In the TAM group, the girl who relapsed in CR1 had t(9;22) chromosomal abnormality. No GvHD occurred after BMT. A second transplantation with the same HLA-identical sibling donor had failed to maintain a durable effect. In contrast, the three patients transplanted in CR1 with the BAM regimen benefited from a prolonged second CR after transplantation from the HLA-identical donors (one unrelated, two siblings) donor and the TAM regimen (median, 7.8 years). These three patients were excluded from the evaluation of sequelae.
Long-term effects (sequelae) of TAM vs BAM regimens (CR1-CR4)
The median follow-up for TAM/BAM is, respectively, 8.6 and 7.6 years. Long-term side effects of TAM vs BAM regimens are summarized in Table 3 . In the TAM group, 24/26 living patients (two excluded because of their return to North Africa) were evaluated: 18 boys and six girls. The median age at the BMT and at the last evaluation for males/females, was, respectively, 7.2/7.4 and 17.3/16.0 years. The final height was obtained in nine males who achieved a median height of 160 cm (range: 152-172) and in four girls who achieved a median height of 150 cm (range: 147-152.5). In all, 11 patients had growth hormone deficiency. Among patients with known final height, seven received GH substitution treatment: 5/9 males and 2/4 females. Among male treated patients, only one had a height above 170 cm (172 cm), others ranged between 152 and 163 cm. In the treated girls, the heights are 147 and 150 cm. Among the GH-deficient patients (n ¼ 11), only five received prophylactic (n ¼ 4) or therapeutic central nervous system irradiation in the course of the disease before BMT. The percentiles of initial height prior to transplant to the final height achieved were compared in GH-deficient patients who had a known final height. Prior to transplant, the mean height was À0. Compensated hypothyroidism were present in nine patients, three patients received CNS irradiation before BMT. All deficient patients received substitution therapy. One patient had a thyroidectomy for thyroid carcinoma occurring 5 years post graft.
In all, 16 males had hypogonadism; 12 received androgen therapy, one patient refused the treatment. Among these patients, eight received prophylactic 4 Gy testicular boost during the BMT period and three patients had testicular irradiation for testicular relapse before transplantation. Among the five evaluable girls, four had spontaneous puberty but with biological hypogonadism with abnormalities in gonadotrophin levels. One had delayed puberty and four received substitution therapy.
Concerning the other sequelae observed, three patients developed a focal exostosis independently of GH treatment, four patients developed cataracts, and four patients had microdontia with disturbance in dental development. One patient died in CR2 with secondary CNS cancer. One patient had femoral osteonecrosis diagnosed during the course of chronic GvHD.
In the BAM group, nine were evaluated: five boys in CR1 and four girls (three CR1 and one CR3). One boy showed hypothyroidism, one girl showed hypothyroidism and hypogonadism and one other girl had GH deficiency and associated hypogonadism, which required substitution therapies. In the six remaining patients, no abnormalities were noticed, particularly for linear growth, though final height was achieved in only two patients. Pulmonary function was prospectively evaluated and a review of the data indicates that significant restrictive airway disease was present in four patients in the TAM and three patients in the BAM group.
Discussion
Our study shows that EFS among CR1 patients was comparable with TAM and BAM, comparable to published reports.
14-17 Nine of 36 (25%) CR2 patients in the TAM group had late relapse. For such patients, some data have shown that the 4-year EFS was about 40% when using chemotherapy alone. 18 A recent analysis reported that BMT is better than chemotherapy, regardless of the duration of the first remission, the disease characteristics at diagnosis or the intensity of prior treatment during first remission. 19 Relapse after TAM was 10%, comparable to other reports. 7, 20 All relapsed patients in the TAM group had isolated bone marrow relapse, even in patients without extra cranial or testicular irradiation in addition to TBI. This suggests that prophylactic CNS or testicular irradiation may be unnecessary. 7 In the literature, other limited or larger studies have been published concerning radiationfree regimens in ALL children or comparison data with or without TBI. A retrospective multicenter study analysis of children with ALL under 4 years of age receiving an HLAgenoidentical BMT, following a Bu-based preparative regimen, has been reported. 11 The study population consisted of 21 consecutive children, 16 with initial poor prognostic factors, who were transplanted in CR1. Leukemic recurrence occurred in six patients among 16 transplanted in CR1 (37%). The Nordic Bone Marrow Transplantation Group reported a randomized study that compared CY 120 mg/kg plus either busulfan 16 mg/kg or TBI in pediatric and adult patients with acute or chronic leukemia. 21 The 3-year relapse-free survival was 50% for patients with ALL who received CY/TBI vs 36% for patients who received Bu/CY. This difference was not statistically significant. Ringde´n reported a matched-pair comparison of Bu/CY vs CY/TBI in adults and children with acute leukemia. 22 There were no differences in relapse, treatment-related mortality or leukemia-free survival between the two regimens. The International Bone Marrow Transplant Registry (IBMTR) reported the outcomes specifically in children with ALL who received transplants from HLA-identical sibling donors after being conditioned with CY/TBI vs Bu/CY. 23 The data indicate superior survival and leukemia-free survival rates in recipients of CY/TBI compared with recipient of Bu/CY. The 3-year probability of survival was 55% with TBI/CY and 40% with Bu/CY (univariate P ¼ 0.003). The 3-year probabilities of leukemia-free survival were 50 and 35%, respectively (univariate P ¼ 0.005). In a multivariate analysis, the risk of relapse was similar in the two groups (P ¼ 0.117).
Addition of high-dose Ara-C to the BMT conditioning regimen has been shown to reduce leukemia relapse without increasing toxicity for patients at high risk for leukemia relapse. 24 Addition of melphalan to busulfan in childhood leukemia has demonstrated a potent antileukemic effect.
Concerning the main long-term side effects of the BMT procedure, sequelae should be avoided or decreased if possible, particularly in children. As with the data reported earlier, following TBI for leukemia, children often experienced long-term side effects, especially regarding growth, final height, puberty, fertility and second malignancies. 25, 26 For Bu-containing regimens, these side effects are less, but the pulmonary toxicity may be more evident. In our results, it appears that the majority of evaluable patients in the TAM group experienced a severe growth impairment. Although 11 patients were treated with GH, we have no evidence of catch-up growth following this treatment despite using fTBI. Additional factors, such as previous cranial irradiation, chronic GvHD or hypothyroidism, radiation-induced skeletal dysplasia or use of glucocorticoids, could play an important role in the disturbed growth. 27 Moreover, one patient in the TAM group has been diagnosed as having secondary carcinoma of thyroid 5 years after BMT. As the latency of the appearance is prolonged, a long-term survey is required. Few side effects were observed in the BAM group, except for subclinical pulmonary restriction.
There are much less data and a shorter follow-up with regard to growth velocity following radiation-free regimen in children with ALL. Wingard 28 did not show any difference during the first and second years post-BMT in 47 children treated with either Bu/CY or fTBI/CY, probably because of a shorter follow-up. On the contrary, Michel 29 reported normal growth velocity in 26 long-term survivors with AML treated with Bu-CY and severe growth impairment in those treated with TBI. Growth velocity was found normal in 12 young children with ALL following a Bu-based regimen. 11 Hypothyroidism was recognized in one out of 23 patients in the Bu/CY group vs seven among 17 evaluable patients in the TBI group. No cataract occurred in the Bu/CY group vs 10 among 16 studied in the TBI group (8/9 TBI, 2/7 fTBI). 29 Thyroid function has not been extensively assessed after radiation-free conditioning regimens. Some data suggest that compensated hypothyroidism may be observed after preparative regimens which include Bu, 11, 29 as we observed in a study, which included the patients described in this paper. We reviewed 96 long-term survivors with a followup greater than 3 years, mainly acute leukemia transplanted in our center, for endocrinological damage. Hypothyroidism was observed in two patients in radiation-free regimens vs 24 in the TBI group. Thyroid carcinoma was observed only in the fTBI group (n ¼ 5) at a median time of 7.5 years after treatment (range: 4-11 years) (G Souillet, personal communication, EBMT Maastricht, 2001, p 573).
Severe disturbance in dental development and microdontia were observed in five patients, four with fTBI, one with BAM. The most frequent disturbance in the development found was the formation of a short, V-shaped root as previously described in patients receiving irradiation. 30 The most extensive and severe disturbance occurs during early stages of tooth development when irradiation is administered in children less than 6 years of age. In our experience, such disturbance and microdontia may be also observed with intensive chemotherapy with or without transplantation in children less than 6 years of age.
Concerning exostosis, local or multifocal lesions may appear after irradiation and, in our experience, independently of GH treatment but not after radiation-free regimens. Disturbance of pulmonary function was observed in both our groups. B Bruno reviewed the effects of allogeneic bone marrow transplantation on pulmonary function in 80 children in our institution including patients studied in this series. 31 A significant reduction of forced expiratory volume in 1 s (FEV1) and a significant reduction of the ratio of FEV1 and forced vital capacity (FVC) were observed in the group with busulfan (n ¼ 22) compared to the group with TBI (n ¼ 49). Chronic GvHD was associated with obstructive ventilatory defect with a significant reduction of FEV1 and FEV1/FVC ratio in this group.
In our experience, the antileukemic effect of the TAM protocol is better than the antileukemic effect of the BAM, but more severe late effects are encountered in the TBI group. The recurrence of leukemia in patients receiving the BAM protocol could be partially solved by individualized dose adaptation of Bu to optimize the efficacy of the clinical outcome, as proposed in our recent report.
